雙重特異性抗體療法

多重特異性的開發

1月12日∼13日

在抗體療法的領域，掀起因強化開發多重特異性之抗體的新波。抗體乃藉由同時與2個以上的標的分子結合而得以強化，尤其是在癌的免疫療法等方面有極佳的治療效果。此部會除檢討開發多重特異性、確保安定性和功效時面臨的各種課題外，亦介紹現在進行開發中各種形態的多重特異性抗體。

會期中來自世界各地的研究人員針對抗體開發令人矚目的成果交換意見，展望癌治療應用真正改革醫療技術的可能性等。

重點研習會：該領域的最尖端技術

Treatment of ALL with BiTE Antibody Blinatumomab

Patrick A. Baeuerle, Ph.D., Professor for Immunology; CSO & Senior Vice President, Micromet, Inc.

Bispecific Antibody Therapeutics Made by Dock-and-Lock

David M. Goldenberg, M.D., President, Garden State Cancer Center; CSO & CMO, Immunomedics, Inc.

Trifunctional Antibodies: Combining Passive and Active Immunization for Cancer Therapy

Horst Lindhofer, Ph.D., Founder & CEO, TRION Pharma GmbH

雙重特異性抗體飛躍性的進步

Transcytosis of the Blood Brain Barrier with Bispecific Antibody Therapeutics

J. Michael Elliott, Senior Research Associate, Genentech

Bispecific Digoxigenin-Binding Antibodies for Targeted Payload Delivery

Ulrich Brinkmann, Ph.D., Leader, Pharma Research and Early Development (pRED), Biologics Engineering, Roche Diagnostics GmbH

雙重特異性設計的進化

CVX-241: A VEGF and Ang2 Targeting Bispecific CovX-Body

Venkata Ramana Doppalapudi, Ph.D., Associate Research Fellow, CovX, Biotherapeutic Division of Pfizer

Talk Title to be Announced

Kevin FitzGerald, Ph.D., M.B.A., CEO, f-star GmbH

多重特異性的開發和安全性的問題

Safety Challenges to the Development of Bispecific Antibodies

Rakesh Dixit, Ph.D., Vice President, Research & Development; Global Head, Biologics Safety Assessments, MedImmune

多重特異性治療用蛋白質的生產

Talk Title to be Announced

Jan van de Winkel, Ph.D., CEO, Genmab AS

Anticalins and Beyond - Simple Manufacturing of Next Generation Multispecific Therapeutic Proteins

Laurent Audoly, Ph.D., CSO, Pieris AG